Eubiologics participates in the "Korea 100-Day Mission" training program.

Eubiologics, a vaccine development and manufacturing company, announced on the 6th that it participated in the 'Korea 100 Days Mission' Table Top Exercise (TTX) to examine the global cooperation system for rapid vaccine development and supply in the event of the next pandemic.

This training exercise was jointly promoted by the Ministry of Food and Drug Safety and the Korea Disease Control and Prevention Agency (KDCA) and hosted by the Coalition for Epidemic Preparedness Innovations (CEPI). Participants included the International Vaccine Institute (IVI), domestic and international health organizations, and private companies.

The "100-Day Mission" is a global health security cooperation initiative aimed at securing the capacity to develop and supply key response tools, such as vaccines, treatments, and diagnostic technologies, within 100 days of the outbreak of a new infectious disease.

As a private vaccine development and manufacturing company, Eubiologics participated in this training to examine its vaccine production and supply capabilities in a pandemic situation and its role within the global cooperation system. The training was conducted as a way to examine the full response system from initial response to pathogen acquisition, vaccine development, clinical trials, approval, production, and supply, assuming the outbreak of a hypothetical new infectious disease called "Disease X."

The company examined key bottlenecks that could arise in the actual vaccine supply process, focusing on its cooperative structure with public and international organizations, supply chain response strategy, and regulatory response system.

Eubiologics has experience supplying vaccines to international organizations, including UNICEF, based on prequalification (PQ) certification from the World Health Organization (WHO). The experience gained through large-scale production and supply through international procurement markets is expected to provide a competitive edge in future pandemic response efforts.

A company official said, “In order to respond to a pandemic, we must have both international cooperation and the ability to provide a stable vaccine supply,” adding, “Based on our experience in supplying global public health vaccines, we will prepare to contribute to the rapid and stable supply of vaccines even in infectious disease crises.”